We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
-$263M
Cap. Flow
-$30.3M
Cap. Flow %
-2.33%
Top 10 Hldgs %
46.95%
Holding
119
New
12
Increased
27
Reduced
37
Closed
33
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1 year
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$41.1M
2
MASI icon
Masimo
MASI
+$40.1M
3
GSK icon
GSK
GSK
+$30.1M
4
HCA icon
HCA Healthcare
HCA
+$15.7M
5
RCM icon
R1 RCM Inc. Common Stock
RCM
+$15.4M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$22.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.8M
3
UTHR icon
United Therapeutics
UTHR
+$19M
4
NVST icon
Envista
NVST
+$12.9M
5
HUM icon
Humana
HUM
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 78.97%
2 Miscellaneous 18.23%
3 Industrials 2.8%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CYH icon
1
Community Health Systems
CYH
$410M
$84.6M 6.5%
7,126,711
+737,173
+12% +$8.96M
2020 Q4
5 quarters
BHVN icon
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$76.4M 5.87%
644,666
+329,537
+105% +$41.1M
2021 Q4
1 quarter
GSK icon
3
CALL
GSK
GSK
$99.3B
$67.7M 5.2%
1,242,960
+40,000
+3% +$2.17M
2020 Q4
5 quarters
QQQ icon
4
PUT
Invesco QQQ Trust
QQQ
$475B
$65.3M 5.01%
180,000
-106,600
-37% -$37.9M
2021 Q4
1 quarter
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$64.2M 4.93%
609,939
-223,811
-27% -$21.8M
2020 Q2
7 quarters
GSK icon
6
GSK
GSK
$99.3B
$55.5M 4.26%
1,007,330
+553,566
+122% +$30.1M
2018 Q1
16 quarters
UTHR icon
7
United Therapeutics
UTHR
$22.8B
$52.4M 4.03%
292,234
-99,686
-25% -$19M
2020 Q2
7 quarters
AZN icon
8
AstraZeneca
AZN
$255B
$49.4M 3.8%
372,632
-101,980
-21% -$12.2M
2019 Q4
9 quarters
ASND icon
9
Ascendis Pharma A/S
ASND
$14.8B
$49M 3.76%
417,172
+13,494
+3% +$1.56M
2017 Q4
17 quarters
DHR icon
10
Danaher
DHR
$161B
$46.9M 3.6%
180,218
-11,602
-6% -$2.91M
2018 Q3
14 quarters
TEVA icon
11
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
$38.9M 2.99%
4,143,602
+1,842,104
+80% +$15.4M
2020 Q3
6 quarters
AZN icon
12
CALL
AstraZeneca
AZN
$255B
$38M 2.92%
286,150
– –
2021 Q3
2 quarters
RCM icon
13
DELISTED
R1 RCM Inc. Common Stock
RCM
$36.4M 2.8%
1,361,506
+628,374
+86% +$15.4M
2021 Q2
3 quarters
AVTR icon
14
Avantor
AVTR
$10.9B
$33.7M 2.58%
995,232
-130,233
-12% -$4.65M
2020 Q4
5 quarters
MASI icon
15
DELISTED
Masimo
MASI
$30.4M 2.34%
+208,970
New +$40.1M
2022 Q1
0 quarters
AMRN icon
16
Amarin Corp
AMRN
$238M
$29.5M 2.27%
449,007
-79,658
-15% -$5.26M
2018 Q1
16 quarters
BIIB icon
17
CALL
Biogen
BIIB
$34.8B
$29.5M 2.26%
+140,000
New +$30.4M
2022 Q1
0 quarters
HCA icon
18
HCA Healthcare
HCA
$99.5B
$27.9M 2.14%
111,440
+62,346
+127% +$15.7M
2020 Q1
8 quarters
NVST icon
19
Envista
NVST
$3.7B
$27.7M 2.13%
569,351
-279,947
-33% -$12.9M
2020 Q4
5 quarters
AMRX icon
20
Amneal Pharmaceuticals
AMRX
$6.64B
$22.9M 1.76%
5,491,497
-949,075
-15% -$4.2M
2020 Q2
7 quarters
CLDX icon
21
Celldex Therapeutics
CLDX
$2.18B
$21.7M 1.66%
636,453
+43,975
+7% +$1.41M
2021 Q4
1 quarter
ARKG icon
22
ARK Genomic Revolution ETF
ARKG
$1.99B
$21.6M 1.66%
470,506
-193,978
-29% -$9.25M
2021 Q1
4 quarters
FATE icon
23
Fate Therapeutics
FATE
$218M
$17.7M 1.36%
456,059
+201,269
+79% +$7.79M
2018 Q4
13 quarters
BIIB icon
24
Biogen
BIIB
$34.8B
$16.4M 1.26%
78,003
+44,962
+136% +$9.78M
2021 Q4
1 quarter
MCK icon
25
McKesson
MCK
$117B
$16.1M 1.23%
52,375
-83,736
-62% -$22.8M
2021 Q1
4 quarters
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Eversept Partners held 119 positions worth $1.3B, down 17% from $1.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners's Q1 2022 filing shows 12 new, 27 increased, 37 reduced and 33 closed positions. Its largest new stake was Masimo: 208,970 shares worth $30.4M. The largest sale was McKesson, an estimated $22.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 72% a quarter earlier, followed by Miscellaneous and Industrials.

  • Eversept Partners's largest Q1 2022 buy was Masimo: 208,970 shares worth $30.4M.
  • Eversept Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2022, an estimated $41.1M increase.
  • Eversept Partners's biggest Q1 2022 reduction was McKesson, cutting an estimated $22.8M.
  • Eversept Partners fully exited Humana in Q1 2022, selling an estimated $12.7M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.3B portfolio in Q1 2022.
  • Eversept Partners opened 12 new positions and closed 33 in Q1 2022.
  • Eversept Partners's portfolio value fell 17% quarter-over-quarter to $1.3B.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.